Différences

Ci-dessous, les différences entre deux révisions de la page.

--- 2022_frm_appl_grant_en [2022/02/21 17:18]
remyfroissart [Study of the antagonistic co-evolution between therapeutic bacteriophages and carbapenem-resistant E. coli]
+++ 2022_frm_appl_grant_en [2022/02/21 17:34] (Version actuelle)
remyfroissart
@@ Ligne 1: / Ligne 1: @@
 [[ https://remy-froissart.ouvaton.org/doku.php|Home]]
-s=====Study of the antagonistic co-evolution between therapeutic bacteriophages and carbapenem-resistant E. coli=====
+=====Study of the antagonistic co-evolution between therapeutic bacteriophages and carbapenem-resistant E. coli=====
 Bacterial evolution towards antibiotic resistance is becoming an increasingly pressing global problem. For example, nearly 5 million people die each year worldwide from infection with bacteria associated with one or more antibiotic resistances (Murray et al 2022 Lancet) and predictions are that 10 million people will die each year by 2050 (O'Neill 2016 Rev. Antimicriobiol. Resist). According to the World Health Organisation, a 'post-antibiotic' era - in which common infections and minor injuries can kill - could therefore soon be upon us if nothing is done. Some 20 bacterial species pose a particular threat to global public health, with carbapenem-resistant //E. coli// at the forefront.

Remy Froissart, CNRS